This document provides an overview of microencapsulation. It defines microencapsulation as coating solid, liquid, or gas core materials that are 5-5000 μm in size. Reasons for microencapsulation include sustained release, taste/odor masking, separating incompatible materials, and protecting materials from environmental conditions. Key considerations are the core and coating materials and the release characteristics. Common techniques include solvent evaporation, spray drying, pan coating, and interfacial polymerization. Microencapsulation has various applications and advantages such as converting liquids to powders and preventing gastric irritation, but also has disadvantages like potential toxicity.
Introduction
Structure
Niosomes Vs. Liposome
Advantages & Disadvantages
Properties of Niosomes
Method of Manufacturing
Evaluation of Niosomes
Applications
Marketed products
Introduction
Structure
Niosomes Vs. Liposome
Advantages & Disadvantages
Properties of Niosomes
Method of Manufacturing
Evaluation of Niosomes
Applications
Marketed products
Mucoadhesive drug delivery system interact with the mucus layer covering the mucosal epithelial surface, & mucin molecules & increase the residence time of the dosage form at the site of the absorption.
Mucoadhesive drug delivery system is a part of controlled delivery system.
Since the early 1980,the concept of Mucoadhesion has gained considerable interest in pharmaceutical technology.
combine mucoadhesive with enzyme inhibitory & penetration enhancer properties & improve the patient complaince.
MDDS have been devloped for buccal ,nasal,rectal &vaginal routes for both systemic & local effects.
Hydrophilic high mol. wt. such as peptides that cannot be administered & poor absorption ,then MDDS is best choice.
Mucoadhesiveinner layers called mucosa inner epithelial cell lining is covered with viscoelasticfluid
Composed of water and mucin.
Thickness varies from 40 μm to 300 μm
General composition of mucus
Water…………………………………..95%
Glycoproteinsand lipids……………..0.5-5%
Mineral salts……………………………1%
Free proteins…………………………..0.5-1%
The mechanism responsible in the formation of mucoadhesive bond
Step 1 : Wetting and swelling of the polymer(contact stage)
Step 2 : Interpenetration between the polymer chains and the mucosal membrane
Step 3 : Formation of bonds between the entangled chains (both known as consolidation stage)
Electronic theory
Wetting theory
Adsorption theory
Diffusion theory
Fracture theory
Advantages over other controlled oral controlled release systems by virtue of prolongation of residence of drug in GIT.
Targeting & localization of the dosage form at a specific site
-Painless administration.
-Low enzymatic activity & avoid of first pass metabolism
If MDDS are adhere too tightlgy because it is undesirable to exert too much force to remove the formulation after use,otherwise the mucosa could be injured.
-Some patient suffers unpleasent feeling.
-Unfortunately ,the lack of standardized techniques often leads to unclear results.
-costly drug delivery system
formulation development of Transdermal drug delivery systems i.e. transdermal patches, compostion of transdermal patch, physical methods used to prepare tansdermal patch
Liposomes, Structure of liposome, phospholipids, classification of liposomes, method of preparation of liposomes, mechanism of liposome formation, application of liposomes.
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Mucoadhesive drug delivery system interact with the mucus layer covering the mucosal epithelial surface, & mucin molecules & increase the residence time of the dosage form at the site of the absorption.
Mucoadhesive drug delivery system is a part of controlled delivery system.
Since the early 1980,the concept of Mucoadhesion has gained considerable interest in pharmaceutical technology.
combine mucoadhesive with enzyme inhibitory & penetration enhancer properties & improve the patient complaince.
MDDS have been devloped for buccal ,nasal,rectal &vaginal routes for both systemic & local effects.
Hydrophilic high mol. wt. such as peptides that cannot be administered & poor absorption ,then MDDS is best choice.
Mucoadhesiveinner layers called mucosa inner epithelial cell lining is covered with viscoelasticfluid
Composed of water and mucin.
Thickness varies from 40 μm to 300 μm
General composition of mucus
Water…………………………………..95%
Glycoproteinsand lipids……………..0.5-5%
Mineral salts……………………………1%
Free proteins…………………………..0.5-1%
The mechanism responsible in the formation of mucoadhesive bond
Step 1 : Wetting and swelling of the polymer(contact stage)
Step 2 : Interpenetration between the polymer chains and the mucosal membrane
Step 3 : Formation of bonds between the entangled chains (both known as consolidation stage)
Electronic theory
Wetting theory
Adsorption theory
Diffusion theory
Fracture theory
Advantages over other controlled oral controlled release systems by virtue of prolongation of residence of drug in GIT.
Targeting & localization of the dosage form at a specific site
-Painless administration.
-Low enzymatic activity & avoid of first pass metabolism
If MDDS are adhere too tightlgy because it is undesirable to exert too much force to remove the formulation after use,otherwise the mucosa could be injured.
-Some patient suffers unpleasent feeling.
-Unfortunately ,the lack of standardized techniques often leads to unclear results.
-costly drug delivery system
formulation development of Transdermal drug delivery systems i.e. transdermal patches, compostion of transdermal patch, physical methods used to prepare tansdermal patch
Liposomes, Structure of liposome, phospholipids, classification of liposomes, method of preparation of liposomes, mechanism of liposome formation, application of liposomes.
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
microencapsulation is the part of an pharmaceutics, in that the method of preperation is giving. and all related thing about microencapsulation is given.
thanks you.
This presentation includes information related to the different technologies used for preparation of micro-capsules and also their evaluation parameters.
Microencapsulation for Cosmetic ApplicationMaulana Sakti
A presentation assignment for Sterile Pharmaceutical Products course about microencapsulation for cosmetic applications, Solid-Lipid Nanoparticles, etc.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
2. CONTENTS
Introduction
Reasons for Microencapsulation
Release Mechanisms
Fundamental Consideration
Morphology of Microcapsules
Techniques to Manufacture
Application
Advantages/Disadvantages
References
3. MICROENCAPSULATION
Microencapsulation is defined as the
application of a thin coating to individual
core materials that have an arbitrary
particle-size range from 5 to 5000 µm
(Nokhodchi and Farid 2002)
For solids, liquid and gases
5. REASONS FOR
MICROENCAPSULATION
To make the formulation sustained or
controlled release.
To mask the taste & odour of bitter drugs
A mean of separating incompatible
materials
To protect the drug from environmental
conditions (light, moisture & oxidation)
For converting liquid into free flowing
powders
To prevent the gastric irritation of certain
drugs
Water solubility or dispersability
6. FUNDAMENTAL CONSIDERATIONS
Nature of the core and coating materials.
The stability and release characteristics of the coated
materials.
The microencapsulation method.
7.
8. CORE MATERIAL
The core material can be in liquid or solid in
nature. The composition of the core material can
be varied as the liquid core can include dispersed
and/or dissolved material.
The solid core can be single solid substance or
mixture of active constituents, stabilizers,
diluents, excipients and release- rate retardants
or accelerators.
9. COATING MATERIAL
The selection of coating material decides the
physical and chemical properties of the resultant
microcapsules/microspheres. While selecting a
polymer the product requirements should be
taken into consideration are:
- -stabilization
- - reduced volatility
- - release characteristics
- - environmental conditions, etc.
12. RELEASE MECHANISMS
1)Degradation controlled monolithic system:
Drug releases on degradation of matrix.
2)Diffusion controlled monolithic system:
Drug released by diffusion then degradation of matrix
occurs.
3)Diffusion controlled reservoir system:
Drug from capsule diffuses then rate controlling
membrane erodes.
4)Erosion:
Due to pH and enzymatic hydrolysis.
13. GENERAL METHODS OF
PREPARATION
Determined by some formulation
and technology related factors.
The particle size requirement.
The drug or the protein should
not be, adversely affected by the
process
Reproducibility of the release
profile
No stability problem.
No toxic products associated
with the final product
Nature of polymer
Drug
Intended use
Duration of therapy
14.
15. Microencapsulation Process Nature(Core) S/L Size Range(um)
Air Suspension
Coacervation and phase
seperation
Pan coating
Spray drying and congealing
Solvent evaporation
S
S/L
S
S/L
S/L
35-5000
2-5000
600-5000
600
5-5000
16. CLASSIFICATION
Chemical Process Physico-Chemical
Process
Physico-Mechanical
Process
Interfacial
Polymerization
In situ
Polymeraization
Poly condensation
Solvent
Evaporation
Coacervation and
phase seperation
Sol-gel Encapsulation
Supercritical CO2
assisted
microencapsulation
Spray drying and
congealing
Pan coating
Fluid bed coating
Extrusion
18. AIR SUSPENSION
TECHNIQUES( WURSTER)
Microencapsulation by air suspension technique
consist of the dispersing of solid, particulate core
materials in a supporting air stream and the
spray coating on the air suspended particles.
Within the coating chamber, particles are
suspended on an upward moving air stream.
The design of the chamber and its operating
parameters effect a recalculating flow of the
particles through the coating zone portion of the
chamber, where a coating material, usually a
polymer solution, is spray applied to the moving
particles.
19. During each pass through the coating zone,
the core material receives an increment of
coating material. The cyclic process is
repeated, perhaps several hundred times
during processing, depending on the purpose
of microencapsulation the coating thickness
desired or whether the core material particles
are thoroughly encapsulated. The supporting
air stream also serves to dry the product
while it is being encapsulated. Drying rates
are directly related to the volume
temperature of the supporting air stream.
20.
21.
22. PAN COATING
1- Solid particles are mixed with a dry coating
material.
2- The temperature is raised
so that the coating material melts
and encloses the core particles, and then is
solidified by cooling. Or, the
coating material can be gradually
applied to core particles tumbling in a vessel rather than
being wholly mixed with the core particles from the
start of encapsulation.
23. SPRAY-DRYING & SPRAY-CONGEALING
Microencapsulation by spray-drying is a low-
cost commercial process which is mostly used
for the encapsulation of fragrances, oils and
flavors.
Steps:
1- Core particles are dispersed in a polymer
solution and sprayed into a hot chamber.
2- The shell material solidifies onto the core
particles as the solvent evaporates.
- The microcapsules obtained are of
polynuclear or matrix type.
24.
25. SPRAY-CONGEALING
This technique can be accomplished with
spray drying equipment when the
protective coating is applied as a melt.
1- the core material is dispersed in a
coating material melt.
2- Coating solidification (and
microencapsulation) is accomplished by
spraying the hot mixture into a cool air
stream.- e.g. microencapsulation of
vitamins with digestible waxes for taste
masking.
26.
27. SOLVENT EVAPORATION
(EMULSIFICATION-
EVAPORATION)
Fully developed at end of 1970
Based on the evaporation of the internal phase of an
emulsion by agitation
DEFINITION :
Process of microencapsulation in which deposition of
coating material or polymer around drug or core material
is carried out by the evaporation of volatile solvent in
which polymer is present. Actually creation of
insufficiency of solvent for polymer by evaporation of
solvent results in precipitation of polymer around core
material & formation of microcapsules. Aggitation is
required during this process
28. METHOD OF PREPARATIONS BY
SOLVENT EVAPORATION PROCESS
Two major techniques are used for
microencapsulation by solvent evaporation.
Single emulsion solvent evaporation technique
(O/W & O/O)
Oil in water emulsion technique
Oil in oil emulsion technique
Multiple emulsion solvent evaporation technique.
(W/O/W)
29. OIL-IN-WATER (O/W) EMULSION
Water as nonsolvent to the polymer are in
general preferred.
Extremely economical and negate the recycling of
the external phase
Suitable for the encapsulation of lipophilic active
principles
Microencapsulation of hydrophilic active
principles by this process can pose problems
30.
31. MULTIPLE EMULSIONS:
WATER-IN-OIL-IN-WATER
(W/O/W)
For the efficient encapsulation of water-soluble
active principles
Organic phase acts as a barrier between the two
aqueous compartments preventing the diffusion
of the medicine toward the external aqueous
phase
This process proves much more effective when
the water solubility of the medicine is high (>900
mg/ mL) and prevent partioning of drug into
organic phase
Sometimes viscosity of primary emulsion is
increased to prevent partioning
32.
33. NONAQUEOUS EMULSIONS:
OIL-IN-OIL (O/O)
Continuous & discontinuous phase are oil
and immiscible with each other
For drugs having high hydrophilicity and
gives highest yield
For drugs/polymers that are degraded in
presence of water
More expensive than aqueous methods
Difficult to recycle oil phase
Traces of oil possesses problems
34.
35. INTERFACIAL POLYMERIZATION
Definition; interfacial Polymerization is a
technique in which polymerization of two
monomers, one oil soluble and other water
soluble, takes place and a polymer is
formed at the interface of two immiscible
substances.
This tech is mostly used for the
encapsulation of liquids rather than solids
b/c penetration of monomer to
polymerization zone is much easy from
the liquid state rather than the solid
state.
36. GENERAL METHOD OF
PREPARATION
The process consists of bringing two reactants at
the interface of the dispersed phase and the
continuous phases in emulsion system
This is usually accomplished by emulsifying the
liquid containing first reactant (dispersed phase)
into continuous phase, which is initially devoid of
second reactant
Additional continuous phase containing the
second reactant is then added. The interfacial
polymerization reaction produces a continuous
film of the polymer around the drug.
Microcapsules can be recovered by spray drying
or filtration
38. PROCEDURES ADOPTED FOR
INTERFACIAL POLYMERIZATION
Procedure for water immiscible liquid core
Procedure for water miscible liquid core
Procedure for solid core
39. PROCEDURE FOR WATER
IMMISCIBLE LIQUID CORE
When the core material is lipophilic liquid, the
monomer is dissolved in the liquid core. Usually
isocyanate or acid chloride is user as monomer.
Then this solution is disperesed in aqueous phase
(containing 2nd
monomer) this prpduces
poolymerization of monomers at the interface &
results in formation of the capsule wall
40. PROCEDURE FOR WATER MISCIBLE
LIQUID CORE
Aqueous solution of water soluble drug
(dispersed phase) containing monomer is
dispersed in to an organic phase
(continuous phase) which contain the
emulsifier to form W/O emulsion. When
additional oil containing 2nd
monomer is
added to W/O emulsion, polymer
membrane is formed. Then microcapsules
are separated by different techniques
41. PROCEDURE FOR SOLID CORE
Solid cores are encapsulated by vinyl monomers
that polymerizes by free radical reaction.
Different solvents used
o CCl4
o Chloroform
o Methanol
o Water
Different monomers used
Polyamines (hexamethylene diamine) polyphenol
(hydroxy phenol propane) polybasic acid halide
(sebacoyl chloride)
42. APPLICATIONS OF INTERFACIAL
POLYMERIZATION
Some important applications are as follows;.
Enzymes
Proteins
Artificial cells
Pharmaceuticals
Adsorbants
Hormones and antibiotics
Pigments, oily liquids & polyelectrolytes
43. COACERVATION OR PHASE
SEPARATION TECHNOLOGY
Coacervation is derived from Latin word acervus
means aggregation and the prefix co indicates
the preceding union of the colloidal particles.
This term was first used to described the
phenomenon of phase separation in colloidal
system and thus it was defined as
44. A process in which aqueous colloidal solutionA process in which aqueous colloidal solution
separate upon alteration of thermodynamicseparate upon alteration of thermodynamic
condition of state into two liquid phases, one richcondition of state into two liquid phases, one rich
in colloid i.e. the coacervate & the otherin colloid i.e. the coacervate & the other
containing little colloidcontaining little colloid.
Deposition of this coacervate around drug or core
material form the embryonic capsule & then
appropriate gelling of coacervate resulted in
microcapsules.
45.
46. CORE MATERIAL
The core material or drug which can be
encapsulated by coacervation can be solid, liquid,
gas, liquid slurry, suspension or emulsion and
analgesics, antibiotics, antihistamine,
tranquillizers, iron salts and vitamins
47. WALL MATERIAL
The coating material can be selected from a
variety of natural and synthetic polymers
depending on the core material to be
encapsulated and the desired characteristics.
The amount of coating material used ranges from
3%-30%of the total weight.
Both natural and synthetic colloids can be used,
Hydrophobic colloids are used for encapsulating
water soluble drugs whereas Hydrophobic
colloids are used for encapsulating water
insoluble drugs.
48. METHODS EMPLOYED FOR
COACERVATION
Following methods can be used for coacervation &
the choice of method depend upon the polymer
and the set of conditions which are being used;
Temperature change
Salt addition
Nonsolvent addition
Incompatible polymer addition
polymer-polymer interaction
49. TEMPERATURE CHANGE
By temp. change, phase separation of dissolved
polymer takes place in the form of immiscible
liquid droplets, if drug is present these droplets
surround the core & form microcapsules.
A system that utilizes ethyl cellulose &
cyclohexane at high temp. is an example of
thermally induced microencapsulation.
Ethylcellulose is soluble in cyclohexane elevated
temp. but insoluble at room temp. first of all
ethylcellulose is dispersed in cyclohexane & then
mixture is heated to boiling point so that a
homogenous polymer solution is formed. Then
core material is added in the solution with
continous stirring & mixture is allowed to cool.
50. This results in phase separation of ethylcellulose &
microencapsulation of core material. Further
cooling of mixture to room temp. causes gelation
& solidification of the coating.
51. SALT ADDITION
Soluble inorganic salts can be added to aqueous
solution of water soluble polymers to cause phase
separation. A gelation-water-sodium sulphate is
an example. In this system, phase
separation/coacervation is induced by adding
dropwise 20% solution of sodium sulphate.
52. NONSOLVENT ADDITION
A liquid that is a nonsolvent for a given polymer or
does not dissolve the given polymer can be added
to a solution of polymer to induce phase
separation. The resulting immiscible liquid
polymer is used for encapsulation of an
immiscible core.
Fro example;
Cellulose acetate+ methyl ethyl ketone --------
solution of polymer--------- addition of drug
(scopolamine) -------addition of isopropyl ether
(nonsolvent for polymer) --------- phase
separation & microencapsulation of suspended
drug occur.
53. INCOMPATIBLE POLYMER
INTERACTION
Methylene blue-ethylcellulose-liquid polybutadiene
is an example of microencapsulation by
incompatible polymer addition.
Ethyl cellulose is dissolved in toluene to form
polymer solution. Then methylene blue is
dispersed in polymer solution. Phase separation
is carried out by adding liquid polybutadiene
which is soluble in toluene but incompatible with
ethyl cellulose. Thus causes demixing of ethyl
cellulose & phase separation occur.
54. POLYMER-POLYMER INTERACTION
Interaction of two oppositely charged
polyelectrolyte can result in the formation of a
complex having such reduced solubility that
phase separation separation occur.
e.g. gelatin & acacia are examples of oppositely
charged polyelectrolyte because gelatin has
positive charge whereas acacia possess a
negative charge. Gelatin-gelatin, gelatin-CMC
are examples of other oppositely chaeged
polyelectrolyte used in microencapsulatio.
55. DESCRIPTION OF COACERVATION
Coacervation method is divided into two main
groups
Aqueous phase separation
Simple coacervatio
Complex coacervation
Organic phase separation
56. CHARACTERIZATION
Recovery of formed microspheres
Hydration of microspheres
Drug loading
Encapsulatipon efficiency
Rheological properties
Morphology (SEM,TEM)
FTIR
XRD
TGA/DSC
Drug release
Drug release kinetics
66. POTENTIAL APPLICATIONS OF
MICROSPHERES
Taste and odor masking
Conversion of oils and other liquids to solids for ease of
handling
Protection of drugs against the environment as
moisture , light ,heat , oxidation etc and vice versa i.e.
prevention of pain of injection
Delay of volatilization
Separation of incompatible materials
Improvement of flow properties of powders
Safe handling of toxic substances
Aid in dispersion of water insoluble substances in
aqueous media
Production of sustained release, controlled release and
targeted medications
Reducing dose dumping potential compared to large
implantable devices (Burgess and Hickey 2002).
67. REFERENCES
1-Leon Lachman, Herbert A. Lieberman, Joseph
L. Kanig,“The Theory and Practice of Industrial
Pharmacy”, 3rd edition, pp.420.
2-JYOTHI SRI.S* , A.SEETHADEVI , K.SURIA
PRABHA , P.MUTHUPRASANNA AND
,P.PAVITRA ,International Journal of Pharma
and Bio Sciences MICROENCAPSULATION: A
REVIEW